Jump to content

SOURCE LIST · 07 / CHECK A CLAIM

BPC-157 references show where each claim came from

A source number follows each claim. Online, the link takes you to the study or FDA words behind it.

A source number leads you back to the evidence

A sore knee can send you through many hopeful claims. Each BPC-157 source number points to the study or an FDA source behind the statement.

Most sources deal with animals or with cells grown in a laboratory. Only three brief human accounts appear, while the BPC-157 legal and pharmacy page draws from FDA material.

Meeting dates come from the FDA calendar. Study amounts, percentages, and times remain beside the work that reported them.

The date near a source shows when it was last checked. Animal findings remain marked as animal work, and you can still see how many people took part.

Online, follow the original study title or the linked FDA source when a claim concerns you. On paper, you can see the source number but can’t open that link.

I’d take the bold claim and its source to your doctor. Ask what happened, who took part, and how closely their health matches yours.

  1. Sikiric P, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. ↗
  2. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  3. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
  4. Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. ↗
  5. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
  6. Blagaic AB, et al. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in rats. Eur J Pharmacol. 2004;499(3):289-298. ↗
  7. Stable Gastric Pentadecapeptide BPC 157 — Possible Novel Therapy of Glaucoma and Other Ocular Conditions. Pharmaceuticals (Basel). 2023;16(7):1052. ↗
  8. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18(10):1450. ↗
  9. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
  10. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  11. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024. ↗
  12. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant. Inflammopharmacology. 2025. ↗
  13. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (BPC-157 entries 'BPC-157 (free base)' and 'BPC-157 acetate'; list entry effective September 29, 2023). ↗
  14. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 and Category 2 definitions; 503A/503B framework; January 7, 2025 interim-policy change). ↗
  15. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (guidance landing page; finalized January 2025). ↗
  16. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda lists BPC-157, KPV, TB-500, and MOTs-C as bulk drug substances 'being considered for inclusion on the 503A Bulks List' — listed for discussion, not decided). ↗
  17. Over-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157. Biomedicines. 2021;9(11):1506. ↗
  18. Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats. Pharmaceuticals (Basel). 2023;16(11):1554. ↗
  19. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. ↗
  20. Tohyama Y, et al.. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyltryptophan autoradiographic measurements. Life Sci. 2004;76:345-357. ↗
  21. Boban Blagaic A, et al.. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol. 2005;512:173-179. ↗
  22. Chang CH, et al.. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19:19066-19077. ↗